Document Type
Article
Publication Date
1-16-2026
Abstract
Introduction Single-cell RNA sequencing has elucidated the heterogeneity in cancer. Single-cell glioblastoma (GBM) analyses have also proposed the resemblance of GBM cells to radial glia and outer radial glia (oRG) supporting the hypothesis that remnants of developmental tissue get reactivated in cancer. A recent study isolated neural progenitor cells (NPCs) from developing fetal human brain (gestational week 17-19) and classified NPCs based on their expression of THY1 (CD90), CD24 and EGFR. Ventricular radial glia are THY1−CD24−EGFR+ whereas oRG are THY1−CD24−EGFR−. Early neuron precursors are CD24+THY1−EGFR+ and glial progenitor cells (GPCs) are THY1+EGFR+. GPCs give rise to THY1+EGFR+PDGFRA+ pre-oligodendrocyte progenitor cells. Methods We aimed to apply the classification above to IDH mutant astrocytoma and oligodendroglioma as well as IDHwt GBM samples. We used 3 publicly available datasets: Wang (paired 74 IDHwt primary and recurrent samples), Tirosh (6 primary oligodendroglioma samples) and Venteicher (10 primary IDH mutant astrocytoma). Results In IDH mutant astrocytoma, 82.67% of cells are THY1+. In oligodendroglioma, 80.47% of cells are THY1+ (mostly EGFR+PDGFRA+ in both disease entities). In IDHwt EGFR amplified primary GBM samples, 87.5% of cells are THY1−CD24−EGFR+. This percentage drops to 70.4% in the recurrent setting. THY1−CD24−EGFR− cells increase from 9.7% to 23.1% at recurrence. In IDHwt EGFRwt primary GBM samples, 48.6% of cells are THY1−CD24−EGFR+ and 44.15% are THY1−CD24−EGFR−. In the recurrent setting, 43.26% of cells are THY1−CD24−EGFR+ and 49.58% are THY1−CD24−EGFR−. Conclusion IDH mutant gliomas and IDHwt GBM express different progenitor cell markers. THY1 is highly expressed in IDH mutant gliomas.
Recommended Citation
Alnahhas, Iyad; Kayne, Allison; Khan, Mehak; and Shi, Wenyin, "Single-Cell Rna Sequencing Suggests Different Progenitor Lineages Between IDH Mutant and IDHwt Glioma" (2026). Department of Neurology Faculty Papers. Paper 394.
https://jdc.jefferson.edu/neurologyfp/394
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
PubMed ID
41727340
Language
English
Comments
This article is the author's final published version in Neuro-Oncology Advances, Volume 8, Issue 1, January 2026, Article Number vdag003.
The published version is available at https://doi.org/10.1093/noajnl/vdag003. Copyright © The Author(s) 2026. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.